PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.94%
Negative revenue growth while AVGO stands at 6.32%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-1.44%
Negative gross profit growth while AVGO is at 4.96%. Joel Greenblatt would examine cost competitiveness or demand decline.
1.97%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
1.97%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-19.11%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-11.76%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-19.12%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-5.34%
Share reduction while AVGO is at 0.15%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.03%
Reduced diluted shares while AVGO is at 0.70%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
33.03%
OCF growth above 1.5x AVGO's 9.32%. David Dodd would confirm a clear edge in underlying cash generation.
73.79%
FCF growth above 1.5x AVGO's 9.56%. David Dodd would verify if the firm’s strategic investments yield superior returns.
671.48%
10Y revenue/share CAGR above 1.5x AVGO's 416.86%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
20.97%
5Y revenue/share CAGR under 50% of AVGO's 134.28%. Michael Burry would suspect a significant competitive gap or product weakness.
63.79%
3Y revenue/share CAGR similar to AVGO's 62.33%. Walter Schloss would assume both companies experience comparable short-term cycles.
5748.32%
10Y OCF/share CAGR above 1.5x AVGO's 580.47%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
424.82%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
356.35%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
1262.01%
Net income/share CAGR 1.25-1.5x AVGO's 869.72%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
32.70%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
467.16%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
1672.84%
10Y equity/share CAGR above 1.5x AVGO's 862.23%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
101.52%
5Y equity/share CAGR at 50-75% of AVGO's 165.61%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
76.67%
Below 50% of AVGO's 201.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.09%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-6.22%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
4.70%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
10.33%
BV/share growth above 1.5x AVGO's 5.15%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
No Data
No Data available this quarter, please select a different quarter.
-2.44%
Our R&D shrinks while AVGO invests at 13.26%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-5.12%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.